Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Zynerba Pharma Raises USD13 Million in Venture Financing 12
Partnerships 13
Zynerba Pharma Partners with Lohmann Therapie-Systeme 13
Licensing Agreements 14
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 14
Equity Offering 15
Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 15
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc – Key Competitors 20
Zynerba Pharmaceuticals Inc – Key Employees 21
Zynerba Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 14, 2017: Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights 23
Aug 01, 2017: Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights 26
May 09, 2017: Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights 28
Mar 27, 2017: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights 30
Nov 14, 2016: Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights 32
Aug 11, 2016: Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes 34
May 12, 2016: Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights 36
Mar 14, 2016: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights 38
Product News 40
12/08/2016: Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases 40
Product Approvals 41
Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome 41
Clinical Trials 42
Jan 03, 2017: Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome 42
Dec 05, 2016: Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society 43
Nov 28, 2016: Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society 45
Nov 02, 2016: Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients 46
Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN002 47
Sep 06, 2016: Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis 48
Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures 49
Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures 50
Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid 52
Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Zynerba Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Zynerba Pharma Raises USD13 Million in Venture Financing 12
Zynerba Pharma Partners with Lohmann Therapie-Systeme 13
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 14
Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 15
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc, Key Competitors 20
Zynerba Pharmaceuticals Inc, Key Employees 21
Zynerba Pharmaceuticals Inc, Subsidiaries 22